biostudies-literatureUnknown29(12)Saglimbene V<h4>Background</h4>The comparative effectiveness of treatment with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or their combination in people with albuminuria and cardiovascular risk factors is unclear.<h4>Methods</h4>In a multicenter, randomized, open label, blinded end point trial, we evaluated the effectiveness on cardiovascular events of ACE or ARB monotherapy or combination therapy, targeting BP<130/80 in patients with moderate or severe albuminuria and diabetes or other cardiovascular risk factors. End points included a primary composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for cardiovascular causes and a revised end point of all-cause mortality. Additional end points included ESRD, douJournal of the American Society of Nephrology : JASN2890-2899https://www.ebi.ac.uk/biostudies/studies/S-EPMC6287867biostudies-literatureThe Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial.PMC6287867Maione AMorano STonelli MPalmer SCNicolucci AProcaccini DAJohnson DWLamacchia OVecchio MPellegrini FLucisano GHegbrant JDe Cosmo SGesualdo LPalasciano GSaglimbene VTognoni GLong-Term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) InvestigatorsAriano RSasso APugliese GStrippoli GFMNatale PCraig JCFilardi TRuospo MfalseThe Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial.<h4>Background</h4>The comparative effectiveness of treatment with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or their combination in people with albuminuria and cardiovascular risk factors is unclear.<h4>Methods</h4>In a multicenter, randomized, open label, blinded end point trial, we evaluated the effectiveness on cardiovascular events of ACE or ARB monotherapy or combination therapy, targeting BP<130/80 in patients with moderate or severe albuminuria and diabetes or other cardiovascular risk factors. End points included a primary composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for cardiovascular causes and a revised end point of all-cause mortality. Additional end points included ESRD, dou2018-01-01T00:00:00Z2018 Dec2026-07-16T17:34:37.707Z2025-04-05T20:37:23.468ZS-EPMC62878673042042110.1681/asn.201804044310.1681/ASN.2018040443